Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Wong-Baker Faces Pain Rating Scale

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Wong-Baker Faces Pain Rating Scale. Displaying page 1 of 1.
    EudraCT Number: 2004-001666-40 Sponsor Protocol Number: CZOL446H2202E1 Start Date*: 2005-02-01
    Sponsor Name:Novartis Pharma AG
    Full Title: An international, multicenter, randomized, open-label, safety and efficacy trial of intravenous zoledronic acid administered either once or twice yearly in children with severe osteogenesis imperfe...
    Medical condition: Osteogenesis Imperfecta
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002066-32 Sponsor Protocol Number: BEB-13 Start Date*: 2017-11-10
    Sponsor Name:Amryt Research Limited
    Full Title: Double-blind, Randomised, Vehicle-controlled, Phase III, Efficacy and Safety Study with 24-month Open-label Follow-up of Oleogel-S10 in Patients with Inherited Epidermolysis Bullosa
    Medical condition: Inherited Epidermolysis Bullosa
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) AT (Completed) DE (Completed) ES (Ongoing) GR (Completed) HU (Completed) CZ (Completed) BE (Completed) DK (Completed) IT (Completed) HR (Completed) FR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2016-004290-41 Sponsor Protocol Number: MEOF-002 Start Date*: 2017-04-11
    Sponsor Name:Medical Developments International Limited
    Full Title: A randomised, double-blind, multicentre, placebo controlled study to evaluate the safety and efficacy of methoxyflurane (PENTHROX®) for the treatment of acute pain in children and adolescents from ...
    Medical condition: acute pain in paediatric patients
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004867 10066714 Acute pain LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005336-25 Sponsor Protocol Number: DMKS-2011 Start Date*: 2012-03-23
    Sponsor Name:Chemische Fabrik Kreussler & Co. GmbH
    Full Title: A randomiszed, mono-center, placebo-controlled, double-blind, comparative study to evaluate the efficacy and safety of Dynexan® Mundgel in minors with acute painful sites of the mouth.
    Medical condition: Painful sites in the mouth
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000137-14 Sponsor Protocol Number: PDC-01-0206 Start Date*: 2021-05-04
    Sponsor Name:Cessatech A/S
    Full Title: Pharmacokinetic study of intranasal CT001 in children 1-17 years of age undergoing elective surgical procedures
    Medical condition: Management of acute pain in children 1-17 years with the objective of preventing pain and distress associated with painful medical procedures in children.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10018065 - General disorders and administration site conditions 10033371 Pain PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2022-002955-20 Sponsor Protocol Number: ADENO-beta Start Date*: 2023-11-22
    Sponsor Name:AOU CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO
    Full Title: Double-blind randomized controlled study versus placebo to evaluate the efficacy of mono-administration of betamethasone in children with symptomatic Adenovirus infection (ADENO-beta).
    Medical condition: Pediatric patients diagnosed with symptomatic Adenovirus infection.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10060931 Adenovirus infection PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003285-20 Sponsor Protocol Number: 030(Z)MD22061 Start Date*: 2023-03-13
    Sponsor Name:Angelini Pharma S.p.A.
    Full Title: Phase IV study comparing the efficacy and safety of an alcohol-free formulation of 0.15% benzydamine hydrochloride spray and benzydamine hydrochloride 3mg lozenges in paediatric patients (6-12 year...
    Medical condition: acute sore throat
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004855 10041367 Sore throat LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-004077-32 Sponsor Protocol Number: BCRU/11/Ibu-AOM/001 Start Date*: 2015-12-29
    Sponsor Name:Berlin-Chemie AG
    Full Title: A randomized open-label, multinational, multicentre, phase III clinical study to evaluate the efficacy and safety of Ibuprofen oral suspension 20 mg/ml and Ibuprofen oral suspension 40 mg/ml (Berli...
    Medical condition: Acute otitis media (AOM) is an acute inflammatory disease involving the mucosa of the middle ear. AOM is one of the most frequent complications of upper respiratory tract infections in children. T...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-002858-24 Sponsor Protocol Number: D-CA-60130-452 Start Date*: 2021-12-17
    Sponsor Name:Clementia Pharmaceuticals Inc, an Ipsen Company
    Full Title: A Phase 2, two-part, placebo-controlled, parallel-group, double-blind study to assess the efficacy and safety of 2 dosage regimens of oral IPN60130 for the treatment of fibrodysplasia ossificans pr...
    Medical condition: fibrodysplasia ossificans progressiva (FOP)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10068715 Fibrodysplasia ossificans progressiva PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Ongoing) SE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002935-88 Sponsor Protocol Number: VX18-CTX001-131 Start Date*: 2019-03-13
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Long-term Follow-up Study of Subjects With β-thalassemia or Sickle Cell Disease Treated with Autologous CRISPR-Cas9 Modified Hematopoietic Stem Cells (CTX001)
    Medical condition: Transfusion-dependent β thalassemia (TDT). Severe sickle cell disease (SCD).
    Disease: Version SOC Term Classification Code Term Level
    26.1 10010331 - Congenital, familial and genetic disorders 10043391 Thalassaemia beta PT
    21.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) FR (Ongoing) GR (Prematurely Ended) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000184-40 Sponsor Protocol Number: 20130173 Start Date*: 2014-09-11
    Sponsor Name:Amgen, Inc.
    Full Title: Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta
    Medical condition: Osteogenesis Imperfecta
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10031243 Osteogenesis imperfecta PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) GB (GB - no longer in EU/EEA) HU (Completed) ES (Completed) Outside EU/EEA BG (Completed) PL (Prematurely Ended) BE (Completed) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 15:25:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA